Outcome of 129 pregnancies in polycythemia vera patients: A report of the European LeukemiaNET

As part of the European LeukemiaNET MPN Pregnancy Project, researchers retrospectively analyzed 129 polycythemia vera (PV) pregnancies and found that live birth rate among patients with PV could be significantly improved by the antenatal introduction of PV-specific therapy. Among the pregnancies that received PV-specific therapy 78.2% resulted in live births, compared with 47.6% among pregnancies without PV-specific therapy. Administration of acetylsalicylic acid (ASA) in combination with low-molecular weight heparin (LMWH; P = 0.001) or interferon (alone or in combination with ASA and/or LMWH; P = 0.023) was associated with a statistically significant lower risk of miscarriage than standard antenatal care.